Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the predominant cause of familial Parkinson's disease. We previously reported that parkin-/- mice exhibit nigrostriatal deficits in the absence of nigral degeneration. Parkin has been shown to function as an E3 ubiquitin ligase. Loss of parkin function, therefore, has been hypothesized to cause nigral degeneration via an aberrant accumulation of its substrates. Here we employed a proteomic approach to determine whether loss of parkin function results in alterations in abundance and/or modification of proteins in the ventral midbrain of parkin-/- mice. Two-dimensional gel electrophoresis followed by mass spectrometry revealed decreased abundance of a number of proteins involved in mitochondrial function or oxidative stress. Consistent with reductions in several subunits of complexes I and IV, functional assays showed reductions in respiratory capacity of striatal mitochondria isolated from parkin-/- mice. Electron microscopic analysis revealed no gross morphological abnormalities in striatal mitochondria of parkin-/- mice. In addition, parkin-/- mice showed a delayed rate of weight gain, suggesting broader metabolic abnormalities. Accompanying these deficits in mitochondrial function, parkin-/- mice also exhibited decreased levels of proteins involved in protection from oxidative stress. Consistent with these findings, parkin-/- mice showed decreased serum antioxidant capacity and increased protein and lipid peroxidation. The combination of proteomic, genetic, and physiological analyses reveal an essential role for parkin in the regulation of mitochondrial function and provide the first direct evidence of mitochondrial dysfunction and oxidative damage in the absence of nigral degeneration in a genetic mouse model of Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, mitophagy deficiency favored by ablation of Prkn (Palacino et al, 2004; Pickrell et al, 2015) or Pink1 (Gautier et al, 2008) sensitizes mice to oxidative stress, while worsening neural damage when combined with mitochondrial dysfunction (mitochondrial DNA [mtDNA] mutator‐prkn/parkin‐KO mice) (Pickrell et al, 2015).”
From Autophagy in major human diseases (2021) · cites this paper as Palacino et al, 2004
In the citing paper
“Both Pink1 and Parkin knockout mice exhibit increased ROS levels and mitochondrial dysfunction (43, 44), and persistent increased ROS is one of the important factors in accelerating cellular senescence (42, 45).”
From Impaired mitophagy leads to cigarette smoke stress‐induced cellular senescence: implications for chronic obstructive pulmonary disease (2015) · cites this paper as [43]
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Research works printed but not linked: 5
- Jenner, 1996, Neurology, 47, 5161
- Koller, 1986, Neurology, 36
- Darios, 2003, Hum. Mol. Genet., 12, 517, 10.1093/hmg/ddg044 · doi:10.1093/hmg/ddg044 · Paper page
- Klose, 1999, Methods Mol. Biol., 112, 67
- Dubin, 1989, Mol. Cell. Biol., 9, 1083
Cited by
Items 301–400 of 1,000
Current perspective of mitochondrial biology in Parkinson's disease
Kaidery, N. A., & Thomas, B. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.001 · Cited by 100
Glucose metabolism impairment in Parkinson’s disease
Dai, C., Tan, C., Zhao, L., Liang, Y., Liu, G., Liu, H., Zhong, Y., Liu, Z., Mo, L., Liu, X., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110672 · Cited by 99
Fernandez-Checa, J. C., Fernandez, A., Morales, A., Mari, M., Garcia-Ruiz, C., & Colell, A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556113 · Cited by 98
Parkin promotes intracellular A 1-42 clearance
Burns, M. P., Zhang, L., Rebeck, G. W., Querfurth, H. W., & Moussa, C. E.-H. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp258 · Cited by 98
Loss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice
Noda, S., Sato, S., Fukuda, T., Tada, N., Uchiyama, Y., Tanaka, K., & Hattori, N. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104717 · Cited by 100
A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin
Omura, T., Kaneko, M., Okuma, Y., Orba, Y., Nagashima, K., Takahashi, R., Fujitani, N., Matsumura, S., Hata, A., Kubota, K., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04155.x · Cited by 98
Inflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
Mitochondria and Energetic Depression in Cell Pathophysiology
Seppet, E. K., Puurand, M., Peetsalu, A., Gizatullina, Z. Z., Nguyen, H. P., Vielhaber, S., Wussling, M. H. P., Trumbeckaitė, S., Arandarčikaitė, O., Jerzembek, D., et al. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10052252 · Cited by 97
Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1
Burbulla, L. F., Fitzgerald, J. C., Stegen, K., Westermeier, J., Thost, A.-K., Kato, H., Mokranjac, D., Sauerwald, J., Martins, L. M., Woitalla, D., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.103 · Cited by 97
Autophagy in adipose tissue biology
Zhang, Y., Zeng, X., & Jin, S. V. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.09.004 · Cited by 97
Molecular Insights into Parkinson's Disease
Rochet, J., Hay, B. A., & Guo, M. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00011-4 · Cited by 96
Kaludercic, N., & Giorgio, V. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3869610 · Cited by 97
Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Cassano, T., Pace, L., Bedse, G., Michele Lavecchia, A., De Marco, F., Gaetani, S., & Serviddio, G. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666151218132725 · Cited by 95
Giaime, E., Yamaguchi, H., Gautier, C. A., Kitada, T., & Shen, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040501 · Cited by 95
Self-citationExperimental models of Parkinson's disease: Challenges and Opportunities
Lal, R., Singh, A., watts, S., & Chopra, K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176819 · Cited by 95
Mitochondrial control of cell bioenergetics in Parkinson’s disease
Requejo-Aguilar, R., & Bolaños, J. P. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.012 · Cited by 96
Parkin reverses intracellular β‐amyloid accumulation and its negative effects on proteasome function
Rosen, K. M., Moussa, C. E. ‐., Lee, H., Kumar, P., Kitada, T., Qin, G., Fu, Q., & Querfurth, H. W. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22178 · Cited by 95
Rango, M., Bonifati, C., & Bresolin, N. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600192 · Cited by 95
Mitochondrial dynamics, cell death and the pathogenesis of Parkinson’s disease
Büeler, H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0465-0 · Cited by 95
Ambivero, C. T., Cilenti, L., Main, S., & Zervos, A. S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.09.004 · Cited by 94
Martin, S. A., Hewish, M., Sims, D., Lord, C. J., & Ashworth, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2836 · Cited by 94
Pirooznia, S. K., Yuan, C., Khan, M. R., Karuppagounder, S. S., Wang, L., Xiong, Y., Kang, S. U., Lee, Y., Dawson, V. L., & Dawson, T. M. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00363-x · Cited by 94
Biochemical aspects of the neuroprotective mechanism of PTEN‐induced kinase‐1 (PINK1)
Mills, R. D., Sim, C. H., Mok, S. S., Mulhern, T. D., Culvenor, J. G., & Cheng, H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05249.x · Cited by 93
Regulation of mitochondrial permeability transition pore by PINK1
Gautier, C. A., Giaime, E., Caballero, E., Núñez, L., Song, Z., Chan, D., Villalobos, C., & Shen, J. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-22 · Cited by 92
Self-citationShedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo?
Cummins, N., & Götz, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2692-9 · Cited by 92
Parkin is a disease modifier in the mutant SOD 1 mouse model of ALS
Palomo, G. M., Granatiero, V., Kawamata, H., Konrad, C., Kim, M., Arreguin, A. J., Zhao, D., Milner, T. A., & Manfredi, G. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201808888 · Cited by 91
Parkinson’s disease mouse models in translational research
Antony, P. M. A., Diederich, N. J., & Balling, R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9330-x · Cited by 91
Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress
Kurz, A., Rabbani, N., Walter, M., Bonin, M., Thornalley, P., Auburger, G., & Gispert, S. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0483-7 · Cited by 91
Age-related diseases as vicious cycles
Belikov, A. V. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.002 · Cited by 90
Hämäläinen, R. H., Landoni, J. C., Ahlqvist, K. J., Goffart, S., Ryytty, S., Rahman, M. O., Brilhante, V., Icay, K., Hautaniemi, S., Wang, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0120-1 · Cited by 90
Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
Madsen, D. A., Schmidt, S. I., Blaabjerg, M., & Meyer, M. (2021) · Cells · doi:10.3390/cells10020283 · Cited by 92
Oxidative stress and Parkinson's disease
Jenner, P. G. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83024-7 · Cited by 89
Patki, G., & Lau, Y. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.026 · Cited by 89
Zhang, X., Zhou, J.-Y., Chin, M. H., Schepmoes, A., Petyuk, V., Weitz, K., Petritis, B. O., Monroe, M. E., Camp, D., Wood, S. A., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr901024z · Cited by 90
Parkin Suppresses the Expression of Monoamine Oxidases
Jiang, H., Jiang, Q., Liu, W., & Feng, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510926200 · Cited by 88
Mitochondrial Dysfunction andα-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First?
Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., & Bellucci, A. (2015) · Parkinson's Disease · doi:10.1155/2015/108029 · Cited by 88
Davison, E. J., Pennington, K., Hung, C., Peng, J., Rafiq, R., Ostareck‐Lederer, A., Ostareck, D. H., Ardley, H. C., Banks, R. E., & Robinson, P. A. (2009) · PROTEOMICS · doi:10.1002/pmic.200900126 · Cited by 88
Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 88
Hauser, D. N., Dukes, A. A., Mortimer, A. D., & Hastings, T. G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.030 · Cited by 87
Neurochemistry and the non-motor aspects of PD
Ferrer, I., López-Gonzalez, I., Carmona, M., Dalfó, E., Pujol, A., & Martínez, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.019 · Cited by 87
Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria
Schmidt, S., Linnartz, B., Mendritzki, S., Sczepan, T., Lubbert, M., Stichel, C. C., & Lubbert, H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq564 · Cited by 87
Wang, H.-L., Chou, A.-H., Yeh, T.-H., Li, A. H., Chen, Y.-L., Kuo, Y.-L., Tsai, S.-R., & Yu, S.-T. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.010 · Cited by 87
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease
Kamienieva, I., Duszyński, J., & Szczepanowska, J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-020-00229-8 · Cited by 87
Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86
“Both Parkin and Pink1 act in synergy to maintain mitochondrial integrity in drosophila (95) andmouse (96)models.”
BackgroundParkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration
Meka, D. P., Müller-Rischart, A. K., Nidadavolu, P., Mohammadi, B., Motori, E., Ponna, S. K., Aboutalebi, H., Bassal, M. A., Annamneedi, A., Finckh, B., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79300 · Cited by 86
Oxidative Stress in Genetic Mouse Models of Parkinson’s Disease
Varçin, M., Bentea, E., Michotte, Y., & Sarre, S. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/624925 · Cited by 86
Bogaerts, V., Theuns, J., & Van Broeckhoven, C. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00342.x · Cited by 86
SUMO ‐regulated mitochondrial function in Parkinson's disease
Souza, A. C. G., Prediger, R. D., & Cimarosti, H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13599 · Cited by 87
Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase
Okatsu, K., Iemura, S., Koyano, F., Go, E., Kimura, M., Natsume, T., Tanaka, K., & Matsuda, N. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.041 · Cited by 86
Haque, M. E., Mount, M. P., Safarpour, F., Abdel-Messih, E., Callaghan, S., Mazerolle, C., Kitada, T., Slack, R. S., Wallace, V., Shen, J., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346437 · Cited by 84
Self-citationMortality, oxidative stress and tau accumulation during ageing in parkin null mice
Rodríguez‐Navarro, J. A., Casarejos, M. J., Menéndez, J., Solano, R. M., Rodal, I., Gómez, A., Yébenes, J. G. D., & Mena, M. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04762.x · Cited by 84
Autophagy in axonal degeneration in glaucomatous optic neuropathy
Munemasa, Y., & Kitaoka, Y. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.03.002 · Cited by 84
Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neuron s
Zheng, L., Bernard-Marissal, N., Moullan, N., D’Amico, D., Auwerx, J., Moore, D. J., Knott, G., Aebischer, P., & Schneider, B. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddw418 · Cited by 84
Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling
Horowitz, M. P., & Greenamyre, J. T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.138 · Cited by 84
Parkin Protects against Mitochondrial Toxins and β-Amyloid Accumulation in Skeletal Muscle Cells
Rosen, K. M., Veereshwarayya, V., Moussa, C. E.-H., Fu, Q., Goldberg, M. S., Schlossmacher, M. G., Shen, J., & Querfurth, H. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512649200 · Cited by 84
Self-citationParkinson’s Disease: The Mitochondria-Iron Link
Muñoz, Y., Carrasco, C. M., Campos, J., Aguirre, P., & Núñez, M. T. (2016) · Parkinson s Disease · doi:10.1155/2016/7049108 · Cited by 84
Cameron, R. B., Beeson, C., & Schnellmann, R. G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00669 · Cited by 84
Mitochondrial lipids in neurodegeneration
Aufschnaiter, A., Kohler, V., Diessl, J., Peselj, C., Carmona-Gutierrez, D., Keller, W., & Büttner, S. (2017) · Cell and Tissue Research · doi:10.1007/s00441-016-2463-1 · Cited by 83
Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Oczkowska, A., Kozubski, W. P., Lianeri, M., & Dorszewska, J. (2014) · Current Genomics · doi:10.2174/1389202914666131210205839 · Cited by 83
Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease.
Lin, T., Liou, C.-W., Chen, S., Chuang, Y., Tiao, M., Wang, P., Chen, J., & Chuang, J. (2009) · PubMed · Cited by 85
Pogson, J. H., Ivatt, R. M., Sanchez-Martinez, A., Tufi, R., Wilson, E., Mortiboys, H., & Whitworth, A. J. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004815 · Cited by 81
Weil, R., Laplantine, E., Curic, S., & Génin, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01243 · Cited by 81
Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
Mounsey, R. B., & Teismann, P. (2011) · Parkinson's Disease · doi:10.4061/2011/617472 · Cited by 81
Bian, M., Liu, J., Hong, X., Yu, M., Huang, Y., Sheng, Z., Fei, J., & Huang, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039953 · Cited by 80
Parkinson’s disease and mitochondrial complex I: a perspective on the Ndi1 therapy
Marella, M., Seo, B. B., Yagi, T., & Matsuno‐Yagi, A. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9249-z · Cited by 80
Cell Death Pathways in Parkinson's Disease: Role of Mitochondria
Yao, Z., & Wood, N. W. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2624 · Cited by 80
Metabolic Stress and Disorders Related to Alterations in Mitochondrial Fission or Fusion.
Babbar, M., & Sheikh, M. S. (2013) · PubMed · Cited by 82
Mitochondrial damage & lipid signaling in traumatic brain injury
Lamade, A. M., Anthonymuthu, T. S., Hier, Z. E., Gao, Y., Kagan, V. E., & Bayır, H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113307 · Cited by 80
Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells
Machida, Y., Chiba, T., Takayanagi, A., Tanaka, Y., Asanuma, M., Ogawa, N., Koyama, A., Iwatsubo, T., Ito, S., Jansen, P. H., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.04.124 · Cited by 79
Can cellular models revolutionize drug discovery in Parkinson's disease?
Schüle, B., Pera, R. A. R., & Langston, J. W. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.014 · Cited by 79
Mitochondrial proteomics in free radical research
Bailey, S. M., Landar, A. L., & Darley-Usmar, V. M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.10.011 · Cited by 78
Agrawal, S., Singh, A. K., Tripathi, P., Mishra, M., Singh, P. K., & Singh, M. P. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8696-7 · Cited by 78
miR-103a-3p regulates mitophagy in Parkinson’s disease through Parkin/Ambra1 signaling
Zhou, J., Zhao, Y., Li, Z., Zhu, M., Wang, Z., Li, Y., Xu, T., Feng, D., Zhang, S., Tang, F., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105197 · Cited by 78
Naoi, M., Maruyama, W., & Shamoto‐Nagai, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911059 · Cited by 77
Yasuda, T., Hayakawa, H., Nihira, T., Ren, Y., Nakata, Y., Nagai, M., Hattori, N., Miyake, K., Takada, M., Shimada, T., et al. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182269ecd · Cited by 76
Role of the Ubiquitin Conjugation System in the Maintenance of Mitochondrial Homeostasis
Neutzner, A., Benard, G., Youle, R. J., & Karbowski, M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.012 · Cited by 76
Thomas, B., von Coelln, R., Mandir, A. S., Trinkaus, D. B., Farah, M. H., Lim, K., Calingasan, N. Y., Beal, M. F., Dawson, V. L., & Dawson, T. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.021 · Cited by 76
Mitochondrial dysfunctions in Parkinson's disease
Gautier, C., Corti, O., & Brice, A. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.06.003 · Cited by 76
Afonso, V., Santos, G. M., Collin, P., Khatib, A., Mitrovic, D. R., Lomri, N., Leitman, D. C., & Lomri, A. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.05.014 · Cited by 77
Kumar, M., Acevedo-Cintrón, J. A., Jhaldiyal, A., Wang, H., Andrabi, S. A., Eacker, S. M., Karuppagounder, S. S., Brahmachari, S., Chen, R., Kim, H., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.07.013 · Cited by 76
Smolders, S., & Broeckhoven, C. V. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00935-4 · Cited by 75
Kitazawa, M., Anantharam, V., Yang, Y., Hirata, Y., Kanthasamy, A., & Kanthasamy, A. G. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.08.035 · Cited by 75
Zanon, A., Kalvakuri, S., Raković, A., Foco, L., Guida, M., Schwienbacher, C., Serafin, A., Rudolph, F., Trilck, M., Grünewald, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx132 · Cited by 75
Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases
Ren, Y., Jiang, H., Ma, D., Nakaso, K., & Feng, J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq550 · Cited by 74
Arif, I. A., & Khan, H. A. (2010) · Toxicology and Industrial Health · doi:10.1177/0748233710362382 · Cited by 74
Cross-talk between mitochondria and proteasome in Parkinson’s disease pathogenesis
Martins-Branco, D. A., Arduíno, D. M., Esteves, A. R., Silva, D. F. F., Cardoso, S. M., & Oliveira, C. R. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00017 · Cited by 74
Molecular insights into Parkinson's disease
Thomas, B., & Beal, M. F. (2011) · F1000 Medicine Reports · doi:10.3410/m3-7 · Cited by 74
Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons
Son, J. H., Kawamata, H., Yoo, M. S., Kim, D. J., Lee, Y. K., Kim, S., Dawson, T. M., Zhang, H., Sulzer, D., Yang, L., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03257.x · Cited by 74
Rani, L., & Mondal, A. C. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.09.010 · Cited by 74
SUN, F., KANTHASAMY, A. G., ANANTHARAM, V., & KANTHASAMY, A. G. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.001 · Cited by 73
Mitophagy and Its Contribution to Metabolic and Aging-Associated Disorders
Liu, L., Liao, X., Wu, H., Li, Y., Zhu, Y., & Chen, Q. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8013 · Cited by 72
Genetic models of Parkinson disease
Lim, K., & Ng, C.-H. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.005 · Cited by 72
A Mechanistic Review of Mitophagy and Its Role in Protection against Alcoholic Liver Disease
Williams, J. A. R., & Ding, W. (2015) · Biomolecules · doi:10.3390/biom5042619 · Cited by 72
Ubiquitin–proteasome system dysfunction in Parkinson’s disease: current evidence and controversies
Lim, K.-L. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.6.769 · Cited by 71
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease
Ambrosi, G., Ghezzi, C., Sepe, S., Milanese, C., Payán‐Gómez, C., Bombardieri, C. R., Armentero, M., Zangaglia, R., Pacchetti, C., Mastroberardino, P. G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.008 · Cited by 71
Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento
de Pereira, U. T., Marín, D. S., Villada, H. C., de Pereira, U. T., Ibarra, M., Grupo de Investigación “Applied Neuroscience”, N. R., Gámez-Cárdenas, M., & de Pereira, U. T. (2018) · Salud UIS · doi:10.18273/revsal.v50n1-2018008 · Cited by 75
Parkinson's disease: from causes to mechanisms
Corti, O., Hampe, C., Darios, F. D., Ibáñez, P., Ruberg, M., & Brice, A. (2004) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2004.10.009 · Cited by 71
Zabel, C., Šagi, D., Kaindl, A. M., Steireif, N., Kläre, Y., Mao, L., Peters, H., Wacker, M. A., KLEENE, R. B., & Klose, J. (2006) · Journal of Proteome Research · doi:10.1021/pr0601077 · Cited by 71
Self-citationHigh reproducibility of large‐gel two‐dimensional electrophoresis
Challapalli, K. K., Zabel, C., Schuchhardt, J., Kaindl, A. M., Klose, J., & Herzel, H. (2004) · Electrophoresis · doi:10.1002/elps.200405979 · Cited by 71
Self-citationGenetically engineered mouse models of Parkinson's disease
Crabtree, D. M., & Zhang, J. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.019 · Cited by 70
Metadata
- Authors
- Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Shen, Jie
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 279
- Issue
- 18
- Pages
- 18614-18622
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2140647923
- Cited by
- 995
- References
- 66
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 34 · 2023: 29 · 2022: 27 · 2021: 44 · 2020: 51 · 2019: 39 · 2018: 41 · 2017: 32 · 2016: 41 · 2015: 41 · 2014: 42 · 2013: 60 · 2012: 49
- FWCI
- 42.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6031 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- Parkin, Parkinson's disease, mitochondrial dysfunction, oxidative stress, E3 ubiquitin ligase, nigrostriatal pathway, complex I, cytochrome c oxidase, respiratory capacity, lipid peroxidation, protein peroxidation, serum antioxidant capacity, metabolic abnormalities
- MeSH terms
- Animals, Antioxidants, Basal Ganglia, Mitochondria, Oxidative Phosphorylation, Parkinson Disease, Protein Processing, Post-Translational, Weight Gain, Reactive Oxygen Species, Mice, Knockout, Oxidative Stress, Cell Respiration, Mitochondrial Proteins, Mitochondrial Diseases, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.